MAXIGEN BIOTECH is accelerating its global transformation from a manufacturer to a branded company. General Manager Ching-Ting Chen stated that the company aims to increase its brand-driven revenue contribution from the current 60% to 80% by 2030. This year, it will establish a U.S. subsidiary for business operations, with medium- to long-term manufacturing also planned to move to the United States.
When asked whether reciprocal tariffs would have an impact, MAXIGEN explained that, for now, tariffs are mostly absorbed by customers and the effect remains limited. However, exchange rate risks caused by New Taiwan Dollar appreciation are more challenging. To reduce uncertainty, the company has negotiated with clients on sharing the burden to mitigate volatility.
In response to demographic and healthcare trends—including the global population aged 65 and above projected to surpass 16.7% by 2030, and annual healthcare expenditure growth of 7.8% in Southeast Asia and South America—MAXIGEN is focusing on high-potential fields such as orthopedics, ophthalmology, chronic disease management, and regenerative medicine. Chen emphasized that the company is advancing high-margin product lines, strengthening vertically integrated supply chains, and expanding its presence in the U.S. market along with strategic mergers and acquisitions, with the goal of building a globally resilient medical innovation enterprise.
The company stressed that the U.S. market is central to its global strategy. It will prioritize establishing sales and regulatory teams, partnering with CDMO firms to reduce tariff pressures, and gradually extending operations into Latin America. At the same time, it plans to build local logistical support systems. In the future, MAXIGEN will localize front-end production processes and actively evaluate potential M&A targets to accelerate capacity transfer and strategic expansion.
Recently, the company also initiated a merger and acquisition program, seeking targets with complementary technologies or synergistic distribution channels. Its mid-term objective is to complete at least one strategically meaningful acquisition to strengthen R&D, manufacturing, and brand power, while expanding into high-barrier emerging markets such as drug-device combination products to deepen its product portfolio and broaden market reach.
Over the past five years, MAXIGEN has achieved a compound annual growth rate (CAGR) of 10.4%, reflecting steady growth momentum. In the first half of 2025, consolidated revenue reached NT$386 million, with operating income of NT$121 million, net profit after tax of NT$106 million, and EPS of NT$1.18, demonstrating solid financial health. Revenue for July alone was NT$65.48 million, a 17.02% year-on-year increase, while cumulative revenue for January to July reached NT$451 million, up 26.46% year-on-year. These results indicate that its global market expansion strategy is taking effect, with business momentum continuing to rise.
Resource: 啟動美國投資 和康生：鎖定高齡與再生醫療商機
